blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2785683

EP2785683 - INKT CELL MODULATORS AND METHODS OF USING THE SAME [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  11.12.2020
Database last updated on 09.04.2026
FormerThe patent has been granted
Status updated on  03.01.2020
FormerGrant of patent is intended
Status updated on  08.08.2019
FormerExamination is in progress
Status updated on  12.07.2019
FormerGrant of patent is intended
Status updated on  22.02.2019
FormerExamination is in progress
Status updated on  18.02.2019
FormerGrant of patent is intended
Status updated on  03.10.2018
FormerExamination is in progress
Status updated on  04.09.2018
FormerGrant of patent is intended
Status updated on  15.04.2018
FormerExamination is in progress
Status updated on  09.12.2016
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): AL, MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Ludwig Institute for Cancer Research Ltd.
Stadelhoferstrasse 22
8001 Zürich / CH
[2019/49]
Former [2014/41]For all designated states
The Chancellor, Masters and Scholars of The University of Oxford
University Offices
Wellington Square
Oxford, Oxfordshire OX1 2JD / GB
For all designated states
The University of Birmingham
Edgbaston Birmingham
West Midlands B15 2TT / GB
Inventor(s)01 / CERUNDOLO, Vincenzo
The Chancellor Masters and Scholars
of the University of Oxford
University Offices
Wellington Square
Oxford Oxfordshire OX1 2JD / GB
02 / BESRA, Gurdyal
The University of Birmingham
Edgbaston
Birmingham West Midlands B15 2TT / GB
03 / LIAM, Cox
The University of Birmingham
Edgbaston
Birmingham West Midlands B15 2TT / GB
 [2014/41]
Representative(s)HGF
HGF Limited
4th Floor, 1 City Square
Leeds LS1 2ES / GB
[N/P]
Former [2020/06]HGF Limited
8th Floor
140 London Wall
London EC2Y 5DN / GB
Former [2014/41]Williams, Richard Andrew Norman
HGF Limited
140 London Wall
London EC2Y 5DN / GB
Application number, filing date12798262.730.11.2012
[2020/06]
WO2012EP74140
Priority number, dateUS201161565287P30.11.2011         Original published format: US 201161565287 P
[2014/41]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013079687
Date:06.06.2013
Language:EN
[2013/23]
Type: A1 Application with search report 
No.:EP2785683
Date:08.10.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 06.06.2013 takes the place of the publication of the European patent application.
[2014/41]
Type: B1 Patent specification 
No.:EP2785683
Date:05.02.2020
Language:EN
[2020/06]
Search report(s)International search report - published on:EP06.06.2013
ClassificationIPC:C07C233/18, A61K45/06
[2018/07]
CPC:
A61K31/16 (EP,US); A61J1/14 (US); A61K31/165 (EP,US);
A61K39/0011 (EP,US); A61K39/001106 (EP,US); A61K39/001119 (EP,US);
A61K39/001124 (EP,US); A61K45/06 (EP,US); A61P35/00 (EP);
C07C233/18 (EP,US); C07K16/2818 (US); C07K16/30 (US);
C07C2601/14 (EP,US); C07C2601/18 (EP,US); C07K2317/21 (US);
C07K2317/24 (US) (-)
Former IPC [2014/41]C07C233/18, A61K31/16, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/41]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:INKT-ZELLMODULATOREN UND VERWENDUNGSVERFAHREN DAFÜR[2014/41]
English:INKT CELL MODULATORS AND METHODS OF USING THE SAME[2014/41]
French:MODULATEURS DE CELLULE INKT ET LEURS PROCÉDÉS D'UTILISATION[2014/41]
Entry into regional phase27.06.2014National basic fee paid 
27.06.2014Designation fee(s) paid 
27.06.2014Examination fee paid 
Examination procedure27.06.2014Examination requested  [2014/41]
08.01.2015Amendment by applicant (claims and/or description)
04.01.2016Despatch of a communication from the examining division (Time limit: M04)
12.04.2016Reply to a communication from the examining division
30.11.2016Despatch of a communication from the examining division (Time limit: M06)
12.06.2017Reply to a communication from the examining division
16.04.2018Communication of intention to grant the patent
24.08.2018Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
04.10.2018Communication of intention to grant the patent
14.02.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
14.02.2019Fee for grant paid
14.02.2019Fee for publishing/printing paid
04.03.2019Communication of intention to grant the patent
11.07.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
09.08.2019Communication of intention to grant the patent
18.12.2019Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  04.01.2016
Opposition(s)06.11.2020No opposition filed within time limit [2021/02]
Fees paidRenewal fee
27.11.2014Renewal fee patent year 03
26.11.2015Renewal fee patent year 04
29.11.2016Renewal fee patent year 05
29.11.2017Renewal fee patent year 06
29.11.2018Renewal fee patent year 07
21.11.2019Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL05.02.2020
CY05.02.2020
EE05.02.2020
FI05.02.2020
HR05.02.2020
LT05.02.2020
LV05.02.2020
MC05.02.2020
MK05.02.2020
MT05.02.2020
PL05.02.2020
RO05.02.2020
RS05.02.2020
SI05.02.2020
SK05.02.2020
SM05.02.2020
TR05.02.2020
BG05.05.2020
NO05.05.2020
GR06.05.2020
IS05.06.2020
[2022/31]
Former [2022/27]CY05.02.2020
EE05.02.2020
FI05.02.2020
HR05.02.2020
LT05.02.2020
LV05.02.2020
MC05.02.2020
MT05.02.2020
PL05.02.2020
RO05.02.2020
RS05.02.2020
SI05.02.2020
SK05.02.2020
SM05.02.2020
TR05.02.2020
BG05.05.2020
NO05.05.2020
GR06.05.2020
IS05.06.2020
Former [2022/26]EE05.02.2020
FI05.02.2020
HR05.02.2020
LT05.02.2020
LV05.02.2020
MC05.02.2020
PL05.02.2020
RO05.02.2020
RS05.02.2020
SI05.02.2020
SK05.02.2020
SM05.02.2020
TR05.02.2020
BG05.05.2020
NO05.05.2020
GR06.05.2020
IS05.06.2020
Former [2021/31]EE05.02.2020
FI05.02.2020
HR05.02.2020
LT05.02.2020
LV05.02.2020
MC05.02.2020
PL05.02.2020
RO05.02.2020
RS05.02.2020
SI05.02.2020
SK05.02.2020
SM05.02.2020
BG05.05.2020
NO05.05.2020
GR06.05.2020
IS05.06.2020
Former [2021/13]EE05.02.2020
FI05.02.2020
HR05.02.2020
LT05.02.2020
LV05.02.2020
PL05.02.2020
RO05.02.2020
RS05.02.2020
SI05.02.2020
SK05.02.2020
SM05.02.2020
BG05.05.2020
NO05.05.2020
GR06.05.2020
IS05.06.2020
Former [2020/50]EE05.02.2020
FI05.02.2020
HR05.02.2020
LT05.02.2020
LV05.02.2020
RO05.02.2020
RS05.02.2020
SK05.02.2020
SM05.02.2020
BG05.05.2020
NO05.05.2020
GR06.05.2020
IS05.06.2020
Former [2020/49]FI05.02.2020
HR05.02.2020
LT05.02.2020
LV05.02.2020
RO05.02.2020
RS05.02.2020
SK05.02.2020
SM05.02.2020
BG05.05.2020
NO05.05.2020
GR06.05.2020
IS05.06.2020
Former [2020/48]FI05.02.2020
HR05.02.2020
LT05.02.2020
LV05.02.2020
RO05.02.2020
RS05.02.2020
SM05.02.2020
BG05.05.2020
NO05.05.2020
GR06.05.2020
IS05.06.2020
Former [2020/47]FI05.02.2020
HR05.02.2020
LT05.02.2020
LV05.02.2020
RS05.02.2020
BG05.05.2020
NO05.05.2020
GR06.05.2020
IS05.06.2020
Former [2020/40]FI05.02.2020
HR05.02.2020
LV05.02.2020
RS05.02.2020
BG05.05.2020
NO05.05.2020
GR06.05.2020
IS05.06.2020
Former [2020/39]FI05.02.2020
HR05.02.2020
LV05.02.2020
RS05.02.2020
BG05.05.2020
NO05.05.2020
GR06.05.2020
Former [2020/38]FI05.02.2020
HR05.02.2020
LV05.02.2020
RS05.02.2020
NO05.05.2020
GR06.05.2020
Former [2020/37]FI05.02.2020
HR05.02.2020
LV05.02.2020
RS05.02.2020
NO05.05.2020
Former [2020/35]FI05.02.2020
NO05.05.2020
Cited inInternational search[IA] WO2010106215  (CONSEJO SUPERIOR INVESTIGACION et al.)
by applicantWO0002058
 US2010284965
 US5474935
 US5139941
 US5622856
 US5658776
 US5773289
 US5789390
 US5834441
 US5863541
 US5851521
 US5252479
 US5792453
 US5824544
 US5707618
 US5693509
 US5670488
 US5585362
 US5856152
 US5879934
 US5849571
 US5830727
 US5661033
 US5328688
 US5631237
 WO0107917
 WO9633739
   HIGUCHI; STELLA: "Pro-drugs as Novel Delivery Systems", vol. 14
   ROCHE,: "Bioreversible Carriers in Drug Design", 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS
   SIMPSON ET AL., NATURE REV, vol. 5, 2005, pages 615 - 625
   GURE ET AL., CLIN CANCER RES, vol. 11, 2005, pages 8055 - 8062
   VELAZQUEZ ET AL., CANCER IMMUN, vol. 7, 2007, pages 1 1
   ANDRADE ET AL., CANCER IMMUN, vol. 8, 2008, pages 2
   TINGUELY ET AL., CANCER SCIENCE, 2008
   NAPOLETANO ET AL., AM J OF OBSTET GYN, vol. 198, 2008, pages 99 E91 - 97
   SCANLAN ET AL., IMMUNOL REV, vol. 188, 2002, pages 22 - 32
   BENDER ET AL., CANCER IMMUNOL, vol. 7, 2007, pages 16
   ATANACKOVIC ET AL., PNAS, vol. 105, 2008, pages 1650 - 1655
   JAGER ET AL., PNAS, vol. 103, 2006, pages 14453 - 14458
   VAN BAREN ET AL., J CLIN ONCOL, vol. 23, 2005, pages 9008 - 9021
   VALMORI ET AL., PNAS, vol. 104, 2007, pages 8947 - 8952
   ODUNSI ET AL., PNAS, vol. 104, 2007, pages 12837 - 12842
   DAVIS ET AL., PNAS, vol. 101, 2004, pages 10697 - 10702
   "Cancer Immunology", 2001, KLUWER ACADEMIC PUBLISHERS
   KIM ET AL., J. VIROL., vol. 72, no. 1, 1998, pages 811 - 816
   GNATENKO ET AL., J. INVEST. MED., vol. 45, 1997, pages 87 - 98
   QUANTIN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 2581 - 2584
   STRATFORD PERRICADET ET AL., J. CLIN. INVEST., vol. 90, 1992, pages 626 - 630
   ROSENFELD ET AL., CELL, vol. 68, 1992, pages 143 - 155
   J.M. STEWART; J.D. YOUNG: "Solid Phase Peptide Synthesis, 2nd edition,", 1984, PIERCE CHEMICAL COMPANY
   M. BODANZSKY; A. BODANZSKY: "The Practice of Peptide Synthesis", 1984, SPRINGER VERLAG
   J. H. JONES: "The Chemical Synthesis of Peptides", 1991, OXFORD UNIVERSITY PRESS
   "Applied Biosystems 430A Users Manual", ABI INC.
   G. A. GRANT,: "Synthetic Peptides, A User's Guide", 1992, W. H. FREEMAN & CO.
   E. ATHERTON; R.C. SHEPPARD: "Solid Phase Peptide Synthesis, A Practical Approach", 1989, IRL PRESS
   G.B. FIELDS,: "Methods in Enzymology", vol. 289, 1997, ACADEMIC PRESS, article "Solid-Phase Peptide Synthesis"
   KAKIMI K ET AL., INT J CANCER., 3 February 2011 (2011-02-03)
   KAWADA J, INT J CANCER., 16 March 2011 (2011-03-16)
   GNJATIC S ET AL., CLIN CANCER RES., vol. 15, no. 6, 15 March 2009 (2009-03-15), pages 2130 - 9
   YUAN J ET AL., PROC NATL ACAD SCI U S A., vol. 105, no. 51, 23 December 2008 (2008-12-23), pages 20410 - 5
   SHARMA P ET AL., J IMMUNOTHER., vol. 31, no. 9, November 2008 (2008-11-01), pages 849 - 57
   WADA H ET AL., INT J CANCER., vol. 123, no. 10, 15 November 2008 (2008-11-15), pages 2362 - 9
   DIEFENBACH CS ET AL., CLIN CANCER RES., vol. 14, no. 9, 1 May 2008 (2008-05-01), pages 2740 - 8
   BENDER A ET AL., CANCER IMMUN, vol. 7, 19 October 2007 (2007-10-19), pages 16
   ODUNSI K ET AL., PROC NATL ACAD SCI U S A., vol. 104, no. 31, 31 July 2007 (2007-07-31), pages 12837 - 42
   VALMORI D ET AL., PROC NATL ACAD SCI U S A., vol. 104, no. 21, 22 May 2007 (2007-05-22), pages 8947 - 52
   UENAKA A ET AL., CANCER IMMUN., vol. 7, 19 April 2007 (2007-04-19), pages 9
   KAWABATA R ET AL., INT J CANCER., vol. 120, no. 10, 15 May 2007 (2007-05-15), pages 2178 - 84
   JAGER E ET AL., PROC NATL ACAD SCI U S A., vol. 103, no. 39, 26 September 2006 (2006-09-26), pages 14453 - 8
   DAVIS ID, PROC NATL ACAD SCI U S A., vol. 102, no. 27, 5 July 2005 (2005-07-05), pages 9734
   CHEN Q, PROC NATL ACAD SCI U S A., vol. 101, no. 25, 22 June 2004 (2004-06-22), pages 9363 - 8
   JAGER E, PROC NATL ACAD SCI U S A., vol. 97, no. 22, 24 October 2000 (2000-10-24), pages 12198 - 203
   CARRASCO J ET AL., J IMMUNOL., vol. 180, no. 5, 1 March 2008 (2008-03-01), pages 3585 - 93
   VAN BAREN N ET AL., J CLIN ONCOL., vol. 23, no. 35, 10 December 2005 (2005-12-10), pages 9008 - 21
   KRUIT WH ET AL., INT J CANCER, vol. 117, no. 4, 20 November 2005 (2005-11-20), pages 596 - 604
   MARCHAND M ET AL., EUR J CANCER, vol. 39, no. 1, January 2003 (2003-01-01), pages 70 - 7
   MARCHAND M ET AL., INT J CANCER., vol. 80, no. 2, 18 January 1999 (1999-01-18), pages 219 - 30
   ATANACKOVIC D ET AL., PROC NATL ACAD SCI U S A., vol. 105, no. 5, 5 February 2008 (2008-02-05), pages 1650 - 5
   SO ET AL., MOL CELLS, vol. 7, 1997, pages 178 - 186
   MARASKOVSKY ET AL., CLIN. CANCER RES., vol. 10, 2004, pages 2879 - 2890
   KREIG ET AL., NATURE, vol. 374, 1995, pages 546 - 9
   WEINER ET AL., PNAS USA, vol. 94, 1997, pages 10833 - 10837
   VABULAS ET AL., J. IMMUNOL., vol. 164, 2000, pages 2372 - 2378
   GUNZER ET AL., BLOOD, vol. 106, 2005, pages 2424 - 2432
   MCCARTHY ET AL., JEXP MED, vol. 204, no. 5, 2007, pages 1131 - 44
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.